BIOMARKER:

EGFR exon 20 mutation

C2 | Sensitive

C3 | Sensitive

C2 | Resistant

C3 | Resistant

Show legend

Drug categories

EGFR

Tyrosine Kinase Inhibitors

Immunotherapy

Non Small Cell Lung Cancer

Solid Tumor

FCN-411

EGFR exon 20 mutation|Non Small Cell Lung Cancer|FCN-411

furmonertinib

EGFR exon 20 mutation|Non Small Cell Lung Cancer|furmonertinib

amivantamab-vmjw

EGFR exon 20 mutation|Non Small Cell Lung Cancer|amivantamab-vmjw

tarloxotinib bromide

EGFR exon 20 mutation|Solid Tumor|tarloxotinib bromide

erlotinib

EGFR exon 20 mutation|Non Small Cell Lung Cancer|erlotinib

icotinib

EGFR exon 20 mutation|Non Small Cell Lung Cancer|icotinib

afatinib

EGFR exon 20 mutation|Non Small Cell Lung Cancer|afatinib

Immunotherapy

EGFR exon 20 mutation|Non Small Cell Lung Cancer|Immunotherapy